| Literature DB >> 34697359 |
Jooae Choe1, Hyun Jung Koo1, Joon-Won Kang1, Joon Bum Kim2, Hee Jun Kang3, Dong Hyun Yang4.
Abstract
The purpose of this study was to evaluate whether bicuspid anatomy affects the discrepancy between CT-derived annular size and intraoperative size. We retrospectively analyzed annular measurements in 667 patients who underwent surgical aortic valve replacement (AVR). Preoperative CT measurements of the aortic annulus were compared to surgically implanted valve sizes. To evaluate whether the bicuspid valve affects the differences between CT annulus diameter and surgical AVR size, patients with diameter larger by > 10% (CT-Lg group) on CT, compared to surgical AVR size, were compared with those having size difference < 10% (CT-Sim group). Propensity score matching yielded 183 matched patients from each group. Bicuspid aortic valve annulus parameters significantly correlated with surgical aortic valve size (r = 0.52-0.71; for all, p < 0.01). The most representative measurements corresponded to surgical aortic valve size were area-derived diameters in tricuspid aortic valve (r = 0.69, p < 0.001) and bicuspid without raphe (r = 0.71, p < 0.001), and perimeter-derived diameter in bicuspid with raphe (r = 0.63, p < 0.001). After propensity score matching, native valve type was not different between CT-Sim and CT-Lg groups. In multivariable analysis, the difference between CT-derived diameter and surgical AVR size was affected by the operator factor and types of prosthesis. Bicuspid aortic annulus diameters measured on CT showed a significant correlation with surgical aortic valve size. The difference between CT-derived diameter and surgical AVR size is affected by operator factor and the types of prosthesis but not affected by the bicuspid valve.Entities:
Mesh:
Year: 2021 PMID: 34697359 PMCID: PMC8549004 DOI: 10.1038/s41598-021-00406-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Measurement of virtual ring of aortic annulus on CT. In tricuspid or bicuspid aortic valve with raphe, descending from the sinus Valsalva to left ventricular outflow track, the hinge point of each individual aortic valve cusp is identified to establish the plane of the annulus. Virtual ring of aortic annulus is selected at the plane of the circumferential ring at the basal attachment points of the three aortic cusps. In bicuspid valve without raphe, the plane and level of virtual ring of aortic annulus is determined when the smallest cross-sectional area is drawn, by drawing a line between both basal ends of the cusps and turning the plane 360 around those two points.
Clinical characteristics and echocardiographic findings.
| Variables | Tricuspid | Bicuspid without raphe | Bicuspid with raphe | ||
|---|---|---|---|---|---|
| Age, year | 67.9 ± 10.1 | 61.7 ± 9.0 | 62.0 ± 11.7 | < 0.001 | < 0.001 |
| Sex, male | 211 (58.3) | 69 (49.6) | 126 (75.9) | 0.08 | < 0.001 |
| Prosthetic valve types | < 0.001 | < 0.001 | |||
| Hancock | 71 (19.6) | 16 (11.5) | 26 (15.7) | ||
| SJR | 56 (15.5) | 46 (33.1) | 41 (24.7) | ||
| ATS AP | 56 (15.5) | 29 (20.9) | 40 (24.1) | ||
| CE magna | 144 (39.8) | 31 (22.3) | 41 (24.7) | ||
| Others‡ | 35 (9.7) | 17 (12.2) | 18 (10.8) | ||
| Operator | 0.63 | 0.51 | |||
| Operator 1 | 66 (18.2) | 29 (20.9) | 35 (21.1) | ||
| Operator 2 | 136 (37.6) | 45 (32.4) | 66 (39.8) | ||
| Operator 3 | 35 (9.7) | 10 (7.2) | 12 (7.2) | ||
| Operator 4 | 55 (15.2) | 23 (16.5) | 29 (17.5) | ||
| Operator 5 | 70 (19.4) | 32 (23.0) | 24 (14.5) | ||
| Mitral regurgitation | 37 (10.2) | 7 (5.0) | 12 (7.2) | 0.07 | 0.14 |
| Atrial fibrillation | 63 (17.4) | 16 (11.5) | 31 (18.7) | 0.11 | 0.19 |
| AS dominancy | 249 (68.8) | 130 (93.5) | 124 (74.7) | < 0.001 | < 0.001 |
| Pure AS | 169 (46.7) | 105 (75.5) | 90 (54.2) | < 0.001 | 0.11 |
| ASr | 80 (22.1) | 25 (18.0) | 34 (20.5) | 0.31 | 0.68 |
| CVA | 71 (19.6) | 16 (11.5) | 18 (10.8) | 0.03 | 0.01 |
| Hypertension | 137 (37.8) | 76 (54.7) | 97 (58.4) | 0.001 | < 0.001 |
| Peripheral arterial disease | 1 (0.3) | 1 (0.7) | 2 (1.2) | 0.48 | 0.43 |
| Rheumatic valvular disease | 50 (13.8) | 6 (0.4) | 14 (8.4) | 0.003 | 0.005 |
| COPD | 15 (4.1) | 1 (0.7) | 7 (4.2) | 0.05 | 0.14 |
| Diabetes mellitus | 85 (23.5) | 20 (14.4) | 41 (24.7) | 0.03 | 0.053 |
| Heart failure | 43 (11.9) | 5 (3.6) | 12 (7.2) | 0.004 | 0.01 |
| History of malignancy | 35 (9.7) | 15 (9.0) | 13 (7.8) | 0.71 | 0.66 |
| Dyslipidemia | 39 (10.8) | 15 (9.0) | 14 (8.4) | 1.00 | 0.69 |
| History of myocardial infarct | 6 (1.7) | 1 (0.7) | 4 (2.4) | 0.68 | 0.51 |
| Liver cirrhosis | 3 (0.8) | 2 (1.2) | 3 (1.8) | 0.62 | 0.61 |
| Chronic renal failure | 26 (7.2) | 2 (1.2) | 7 (4.2) | 0.009 | 0.028 |
| Albumin, g/dL | 3.7 ± 0.4 | 3.8 ± 0.4 | 3.8 ± 0.4 | < 0.001 | < 0.001 |
| BUN, mg/dL | 19.8 ± 9.5 | 16.4 ± 5.5 | 17.9 ± 6.4 | < 0.001 | 0.033 |
| Creatinine, mg/dL | 12.7 ± 1.7 | 13.1 ± 1.6 | 13.6 ± 1.7 | 0.002 | 0.135 |
| BNP, pg/dL | 138 ± 336.5 | 80 ± 207 | 87 ± 202.8 | 0.005 | 0.006 |
| Hemoglobin, g/dL | 12.7 ± 1.7 | 13.1 ± 1.6 | 13.6 ± 1.7 | 0.014 | < 0.001 |
| Preoperative echocardiography | |||||
| LVEF, % | 56.3 ± 12.5 | 60.1 ± 10.5 | 56.4 ± 11.7 | 0.004 | 0.99 |
| LVMI, g/m2 | 148.3 ± 46.0 | 138.6 ± 38.3 | 150.8 ± 47.1 | 0.078 | 0.82 |
| Peak velocity, m/s | 4.3 ± 1.4 | 4.9 ± 1.2 | 4.4 ± 1.3 | < 0.001 | 0.72 |
| Mean pressure gradient, mmHg | 56.5 ± 22.8 | 64.8 ± 23.1 | 55.5 ± 25.6 | 0.003 | 0.90 |
| Postoperative echocardiography | |||||
| LVEF, % | 54.5 ± 12.8 | 60.7 ± 8.6 | 54.6 ± 13.6 | 0.004 | 0.99 |
| LVMI, g/m2 | 218.1 ± 210.0 | 190.1 ± 63.8 | 213.3 ± 77.3 | 0.08 | 0.82 |
| Peak velocity, m/s | 2.7 ± 0.6 | 2.6 ± 0.5 | 2.5 ± 0.6 | < 0.001 | 0.72 |
| Mean pressure gradient, mmHg | 16.1 ± 7.0 | 14.8 ± 5.8 | 14.7 ± 6.0 | 0.003 | 0.903 |
Data are shown as the number of patients with percentages in parentheses or mean ± standard deviation.
AS, aortic stenosis; ASr, aortic stenosis and minimal to mild aortic regurgitation; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CE magna, Carpentier-Edwards PERIMOUNT Magna; COPD, chronic obstructive pulmonary diseases; CVA, cerebrovascular accident; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; SJR, St Jude Medical Regent.
*p values are obtained by comparing between tricuspid and bicuspid without raphe and †between tricuspid and bicuspid with raphe. ‡Valves including Sorin (n = 24), On-X (n = 12), CM TopHat (n = 11), Trifecta (n = 11), Mitroflow (n = 8), Mosaic (n = 3) and Biocor (n = 1).
Correlation between surgical aortic valve size (tissue-annulus diameter) and CT-derived annulus diameters of three types of native aortic valves (r, all data are p < 0.01).
| CT-derived parameter | Tricuspid | Bicuspid with Raphe | Bicuspid without raphe |
|---|---|---|---|
| Maximal annulus diameter, mm | 0.66 | 0.62 | 0.64 |
| Minimal annulus diameter, mm | 0.63 | 0.52 | 0.63 |
| Mean annulus diameter, mm | 0.68 | 0.61 | 0.68 |
| Area-derived diameter, mm | 0.69 | 0.62 | 0.71 |
| Perimeter-derived diameter, mm | 0.65 | 0.63 | 0.70 |
Figure 2Scatter plot to demonstrate the distribution of area-derived annular diameter measured on CT and tissue annular diameter of surgical aortic valve replacement (SAVR).
Figure 3Comparison of GOA measured in surgical aortic valve replacement (SAVR) and CT-derived geometric orifice area (SAVR-CT) according to the native valve types. GOA, geometric orifice area; SAVR, surgical aortic valve replacement.
Surgical aortic valve size and CT measurements.
| Variables | Tricuspid | Bicuspid | Bicuspid | ||
|---|---|---|---|---|---|
| Implanted valve size, mm | 22.3 ± 2.2 | 22.1 ± 2.3 | 23.4 ± 2.2 | 0.73 | < 0.001 |
| Tissue annulus diameter, mm | 22.3 ± 2.3 | 22.0 ± 2.5 | 23.4 ± 2.3 | 0.34 | < 0.001 |
| Intraoperative sizing | |||||
| GOA, cm2 | 3.4 ± 0.7 | 3.3 ± 0.7 | 3.7 ± 0.7 | 0.17 | < 0.001 |
| Indexed GOA | 2.0 ± 0.4 | 1.9 ± 0.4 | 2.1 ± 0.4 | 0.20 | 0.001 |
| CT-based SAVR sizing | |||||
| Area-derived diameter, mm | 25.2 ± 3.1 | 24.9 ± 3.4 | 27.0 ± 3.4 | 0.34 | < 0.001 |
| SAVR-CT GOA, cm2 | 3.9 ± 1.0 | 3.76 ± 1.0 | 4.4 ± 1.0 | 0.20 | < 0.001 |
| Indexed SAVR-CT GOA, cm2 | 2.4 ± 0.5 | 2.3 ± 0.5 | 2.6 ± 0.5 | 0.21 | < 0.001 |
| GOACT − GOASAVR, cm2 | 1.2 ± 0.2 | 1.2 ± 0.2 | 1.2 ± 0.2 | 0.93 | 0.19 |
| CT-derived parameters | |||||
| Maximal annulus diameter, mm | 28.3 ± 3.5 | 27.3 ± 4.1 | 30.0 ± 4.0 | 0.03 | < 0.001 |
| Minimal annulus diameter, mm | 22.9 ± 3.1 | 22.8 ± 3.2 | 24.4 ± 3.6 | 0.99 | < 0.001 |
| Mean annulus diameter, mm | 25.6 ± 3.1 | 25.0 ± 3.4 | 27.2 ± 3.6 | 0.67 | < 0.001 |
| Annulus perimeter, mm | 81.1 ± 10.1 | 80.2 ± 11.0 | 87.0 ± 11.1 | 0.73 | < 0.001 |
| Perimeter-derived annulus diameter, mm | 25.8 ± 3.2 | 25.5 ± 3.5 | 27.7 ± 3.5 | 0.66 | < 0.001 |
| Annulus area, mm2 | 507.1 ± 130.0 | 496.5 ± 147.1 | 581.7 ± 152.9 | 0.73 | < 0.001 |
| Area-derived annulus diameter, mm | 25.2 ± 3.1 | 24.9 ± 3.4 | 27.0 ± 3.4 | 0.61 | < 0.001 |
| Area of calcification at the annulus, mm2 | 2.9 ± 9.1 | 9.0 ± 26.6 | 7.4 ± 20.3 | 0.001 | 0.02 |
| Sinus diameter, mm | 38.6 ± 34.0 | 38.4 ± 5.2 | 39.4 ± 4.6 | 0.99 | 0.95 |
| Sinotubular junction diameter, mm | 31.0 ± 4.8 | 32.9 ± 5.5 | 33.7 ± 5.4 | < 0.001 | < 0.001 |
| Ascending aorta tubular portion, mm | 38.3 ± 5.7 | 44.0 ± 6.3 | 42.5 ± 6.5 | < 0.001 | < 0.001 |
| Patient-prosthesis mismatch‡ | 0.13 | 0.17 | |||
| Normal | 279 (77.1) | 116 (83.5) | 137 (82.3) | ||
| Mild/moderate | 81 (22.4) | 23 (16.5) | 29 (17.5) | ||
| Severe | 1 (0.3) | 0 (0) | 0 (0) | ||
Data are shown as the number of patients with percentages in parentheses or mean ± standard deviation.
GOA, geometric orifice area; SAVR, surgical aortic valve replacement.
*p values are obtained by comparing between tricuspid and bicuspid without raphe and †between tricuspid and bicuspid with raphe. ‡p values are obtained by comparing between normal group and the group with mild to severe grade of patient-prosthesis mismatch.
Comparison between patients with > 10% larger diameter on CT from the surgical aortic valve size (CT-Lg, n = 423) and those ≤ 10% range (CT-Sim, n = 244), before and after applying propensity scores.
| Before propensity score matching | After propensity score matching | |||||||
|---|---|---|---|---|---|---|---|---|
| CT-Sim | CT-Lg | SD | CT-Sim | CT-Lg | SD | |||
| Prosthetic valve | < 0.001 | 0.20 | ||||||
| Hancock | 71 (29.1) | 42 (9.9) | − 0.50 | 52 (28.4) | 36 (19.7) | − 0.21 | ||
| SJR | 40 (16.4) | 103 (24.3) | 0.20 | 28 (15.3) | 34 (18.6) | 0.09 | ||
| ATS AP | 30 (12.3) | 95 (22.5) | 0.27 | 23 (12.6) | 35 (19.1) | 0.18 | ||
| CE magna | 88 (36.1) | 128 (30.3) | − 0.12 | 69 (37.7) | 67 (36.6) | − 0.02 | ||
| Others* | 15 (6.1) | 55 (13.0) | 0.24 | 11 (6.0) | 11 (6.0) | < 0.001 | ||
| Operator | < 0.001 | 0.01 | ||||||
| Operator 1 | 85 (34.8) | 45 (10.6) | − 0.60 | 53 (29.0) | 27 (14.8) | − 0.35 | ||
| Operator 2 | 79 (32.4) | 168 (39.7) | 0.15 | 67 (36.6) | 81 (44.3) | 0.16 | ||
| Operator 3 | 25 (10.2) | 32 (7.6) | − 0.09 | 20 (10.9) | 19 (10.4) | − 0.02 | ||
| Operator 4 | 34 (13.9) | 73 (17.3) | 0.09 | 25 (13.7) | 25 (13.7) | < 0.001 | ||
| Operator 5 | 21 (8.6) | 105 (24.8) | 0.44 | 18 (9.8) | 31 (16.9) | 0.21 | ||
| Native valve shape | 0.77 | 0.78 | ||||||
| Tricuspid | 136 (55.7) | 226 (53.5) | − 0.04 | 100 (54.6) | 99 (54.1) | − 0.01 | ||
| Bicuspid without raphe | 51 (20.9) | 88 (20.8) | − 0.002 | 39 (21.3) | 35 (19.1) | − 0.05 | ||
| Bicuspid with raphe | 57 (23.4) | 109 (25.8) | 0.06 | 44 (24.0) | 49 (26.8) | 0.06 | ||
| Age, year | 68.2 ± 9.0 | 63.4 ± 11.2 | < 0.001 | − 0.48 | 68.9 ± 7.8 | 68.0 ± 8.9 | 0.28/0.26† | − 0.11 |
| Sex, male | 130 (53.3) | 276 (65.2) | 0.003 | − 0.24 | 100 (54.6) | 108 (59.0) | 0.46 | 0.09 |
| Atrial fibrillation | 47 (19.3) | 63 (14.9) | 0.18 | − 0.12 | 38 (20.8) | 39 (21.3) | 1.00 | 0.01 |
| AS predominant | 200 (82.0) | 303 (71.6) | 0.004 | − 0.25 | 159 (86.9) | 158 (86.3) | 1.00 | − 0.02 |
| AR predominant | 36 (14.8) | 92 (21.7) | 0.04 | 0.18 | 19 (10.4) | 16 (8.7) | 0.72 | − 0.06 |
| Mitral regurgitation | 23 (9.4) | 33 (7.8) | 0.56 | − 0.06 | 12 (6.6) | 8 (4.4) | 0.49 | − 0.10 |
| CVA | 45 (18.4) | 60 (14.2) | 0.18 | − 0.11 | 36 (19.7) | 37 (20.2) | 1.00 | 0.01 |
| Hypertension | 139 (57.0) | 218 (51.5) | 0.20 | − 0.11 | 103 (56.3) | 101 (55.2) | 0.92 | − 0.02 |
| PAD | 2 (0.8) | 2 (0.5) | 0.97 | − 0.04 | 2 (1.1) | 1 (0.5) | 1.00 | − 0.06 |
| Rheumatic valve | 23 (9.4) | 47 (11.1) | 0.58 | 0.06 | 19 (10.4) | 14 (7.7) | 0.47 | − 0.10 |
| COPD | 8 (3.3) | 15 (3.5) | 1.00 | 0.01 | 5 (2.7) | 6 (3.3) | 1.00 | 0.03 |
| Diabetes mellitus | 50 (20.5) | 96 (22.7) | 0.57 | 0.05 | 44 (24.0) | 49 (26.8) | 0.63 | 0.06 |
| Heart failure | 16 (6.6) | 44 (10.4) | 0.13 | − 0.32 | 11 (6.0) | 11 (6.0) | 1.00 | < 0.001 |
| Malignancy | 19 (7.8) | 44 (10.4) | 0.33 | 0.09 | 17 (9.3) | 26 (14.2) | 0.19 | 0.15 |
| Dyslipidemia | 24 (9.8) | 44 (10.4) | 0.92 | 0.02 | 21 (11.5) | 19 (10.4) | 0.87 | − 0.04 |
| Chronic renal failure | 10 (4.1) | 25 (5.9) | 0.41 | 0.08 | 8 (4.4) | 10 (5.5) | 0.81 | 0.05 |
| History of MI | 4 (1.6) | 7 (1.7) | 1.00 | 0.01 | 4 (2.2) | 2 (1.1) | 0.68 | − 0.09 |
| Liver cirrhosis | 5 (2.0) | 3 (0.7) | 0.25 | − 0.11 | 4 (2.2) | 1 (0.5) | 0.37 | − 0.14 |
| LVEF, % | 58.6 ± 11.7 | 56.2 ± 12.1 | 0.01/0.001† | − 0.20 | 59.4 ± 11.0 | 58.7 ± 10.1 | 0.56/0.07† | − 0.06 |
| LVMI, g/m2 | 142.1 ± 43.4 | 149.7 ± 45.6 | 0.04/0.03† | 0.17 | 140.6 ± 43.2 | 141.8 ± 43.9 | 0.80/0.74† | 0.03 |
| Peak velocity, m/s | 4.5 ± 1.2 | 4.4 ± 1.4 | 0.13/0.21† | − 0.12 | 4.8 ± 0.9 | 4.8 ± 1.0 | 0.94/0.87† | 0.01 |
| Mean PG, mmHg | 58.0 ± 22.4 | 58.1 ± 24.7 | 0.98/0.99† | 0.002 | 58.3 ± 22.1 | 58.3 ± 24.0 | 0.99/0.95† | 0.001 |
Data are shown as the number of patients with percentages in parentheses or mean ± standard deviation unless specified otherwise. When the continuous variables do not follow the normal distribution, t-test result assuming the normality and the Shapiro–Wilk Test indicating the non-normal test are specified in the p-value (p-value in t-test/p-value in Shapiro–Wilk test)†. *Valves including Sorin (n = 24), On-X (n = 12), CM TopHat (n = 11), Trifecta (n = 11), Mitroflow (n = 8), Mosaic (n = 3) and Biocor (n = 1).
AR, aortic regurgitation; AS, aortic stenosis; CE magna, Carpentier-Edwards PERIMOUNT Magna; COPD, chronic obstructive pulmonary diseases; CVA, cerebrovascular accident; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; MI, myocardial infarction; PAD, peripheral arterial disease; PG, pressure gradient; SD, standard deviation; SJR, St Jude Medical Regent.
Univariable and multivariable logistic regression analysis after propensity score matching to discriminate the patients with > 10% larger area-derived annulus diameter on CT (CT-Lg) compared to tissue annulus diameter of prosthetic valve from those ≤ 10% range of differences (CT-Sim).
| Variable | Univariable | Multivariable | ||||||
|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||||
| Age | − 0.01 | 0.99 | [0.96, 1.01] | 0.28 | ||||
| Sex | − 0.18 | 0.84 | [0.55, 1.27] | 0.40 | ||||
| Operator 1 | 1 | 0.01 | 0.003 | |||||
| Operator 2 | 0.86 | 2.37 | [1.35, 4.18] | 0.003 | − 1.32 | 0.27 | [0.12, 0.60] | 0.001 |
| Operator 3 | 0.62 | 1.87 | [0.86, 4.07] | 0.12 | − 1.10 | 0.90 | [0.40, 2.05] | 0.81 |
| Operator 4 | 0.67 | 1.96 | [0.95, 4.07] | 0.07 | − 0.75 | 0.47 | [0.19, 1.14] | 0.10 |
| Operator 5 | 1.22 | 3.38 | [1.61, 7.11] | 0.001 | − 0.56 | 0.57 | [0.25, 1.29] | 0.18 |
| Hancock | 1 | 0.20 | 0.04 | |||||
| SJR | 0.56 | 1.75 | [0.91, 3.38] | 0.09 | − 1.18 | 0.31 | [0.10, 0.91] | 0.03 |
| ATS AP | 0.79 | 2.20 | [1.12, 4.32] | 0.02 | − 0.18 | 0.84 | [0.30, 2.32] | 0.73 |
| CE magna | 0.34 | 1.40 | [0.82, 2.41] | 0.22 | − 0.37 | 0.69 | [0.23, 2.10] | 0.51 |
| Others | 0.37 | 1.44 | [0.57, 3.69] | 0.44 | − 0.65 | 0.52 | [0.20, 1.38] | 0.19 |
| Atrial fibrilation | − 0.03 | 0.97 | [0.59, 1.60] | 0.90 | ||||
| AS dominant | 0.05 | 1.05 | [0.57, 1.91] | 0.88 | ||||
| Mitral regurgitation | 0.43 | 1.54 | [0.61, 3.85] | 0.36 | ||||
| CVA | − 0.03 | 0.97 | [0.58, 1.61] | 0.90 | ||||
| Hypertension | 0.04 | 1.05 | [0.69, 1.58] | 0.83 | ||||
| PAD | 0.70 | 2.01 | [0.18, 22.37] | 0.57 | ||||
| Rheumatic disease | 0.34 | 1.40 | [0.68, 2.88] | 0.36 | ||||
| COPD | − 0.19 | 0.83 | [0.25, 2.77] | 0.76 | ||||
| Diabetes mellitus | − 0.14 | 0.87 | [0.54, 1.39] | 0.55 | ||||
| Heart failure | 0.00 | 1.00 | [0.42, 2.37] | 1.00 | ||||
| Malignancy | − 0.48 | 0.62 | [0.32, 1.18] | 0.15 | ||||
| Dyslipidemia | 0.11 | 1.12 | [0.58, 2.16] | 0.74 | ||||
| CRF | − 0.24 | 0.79 | [0.31, 2.06] | 0.63 | ||||
| History of MI | 0.70 | 0.50 | [0.37, 11.18] | 0.42 | ||||
| Liver cirrhosis | 1.40 | 4.07 | [0.45, 36.74] | 0.21 | ||||
| Ejection fraction | − 0.01 | 0.99 | [0.98, 1.01] | 0.56 | ||||
| LVMI | 0.001 | 1.00 | [0.99, 1.01] | 0.80 | ||||
| Peak velocity, m/s | − 0.01 | 0.99 | [0.80, 1.24] | 0.94 | ||||
| Mean PG, mmHg | 0.00 | 1.00 | [0.99, 1.01] | 0.99 | ||||
| Tricuspid valve | 0.78 | |||||||
| Bicuspid without raphe | − 0.10 | 0.91 | [0.53, 1.55] | 0.72 | ||||
| Bicuspid with raphe | 0.12 | 1.13 | [0.69, 1.84] | 0.64 | ||||
AS, aortic stenosis; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CE magna, Carpentier-Edwards PERIMOUNT Magna; CI, confidence interval; COPD, chronic obstructive pulmonary diseases; CRF, chronic renal failure; CVA, cerebrovascular accident; eGFR, estimated glomerular filtration rate; LVMI, left ventricular mass index; MI, myocardial infarction; PAD, peripheral arterial disease; PG, pressure gradient; SJR, St Jude Medical Regent.